Lundbeck Steps Up Chinese Operations; Revises Lexapro Terms With J&J
This article was originally published in PharmAsia News
Executive Summary
Danish drug maker Lundbeck is increasing its sales force in China and revising its licensing agreement with partner Xian-Janssen - Johnson & Johnson's China subsidiary - to co-market its top-selling antidepressant Lexapro (escitalopram) in China